期刊文献+

拉米夫定耐药HBV毒株RT区变异分析 被引量:13

The mutations analysis of the reverse transcriptase domain of HBV polymerase in Lamivudine-resistant patients
原文传递
导出
摘要 目的研究拉米夫定(LAM)治疗后出现HBV病毒学突破患者HBVRT区变异位点和变异类型。方法研究对象选自2004年4月至2007年3月在苏州大学附属第一医院门诊或住院治疗的慢性乙型肝炎患者,用聚合酶链式反应(PCR)方法扩增LAM治疗后出现HBV病毒学突破患者的血清HBVRT区基因,对PCR产物直接测序,用Chromas2.0软件分析HBVRT区基因的核苷酸和氨基酸差异、变异类型。结果109例患者在拉米夫定耐药后出现病毒学突破,其中94例出现拉米夫定耐药相关性变异,包括YMDD变异93例,单独rtA181T变异1例。13例(11.93%)患者经测序分析未发现YMDD变异,但用限制性内切酶片段长度多态性(RFLP)方法检测,均发现有YMDD变异。测序结果发生变异位点和出现频率:rtM204V/I93例(85.3%)、rtL180M51例(46.9%)、rtV173L/M7例(6.4%)、rtV207M/L/I4例(3.7%)、rtA181T4例(3.7%)、rtT184I/S/M2例(1.8%)、rtM250L2例(1.8%)。变异类型:rtM204V/I、rtA181T、rtM204V/I+rtL180M、rtM204V/I+rtL180M+rtV173M等。结论拉米夫定耐药主要变异类型为rtM204V/I变异,常伴随rtL180M和rtV173L/M变异;少数拉米夫定耐药患者在阿德福韦和恩替卡韦治疗前即已产生阿德福韦和恩替卡韦耐药相关性变异。 Objective To study the nucleotide substitution sites and patterns of the reverse transcriptase (RT) domain of HBV polymerase of patients with viral DNA breakthrough under LAM therapy. Methods Between April 2004 and March 2007, the subjuts were selected from patients with chronic hepatitis B who were treated in the First Affiliated Hospital of Soochow University. HBV strains were amplified by PCR using specific primers flanking B-C regions of RT and S gene. The PCR products were directly analyzed by sequencing. The difference of nucleotide, amino acid and mutation patterns of RT region was classified by using Chromas2. 0 software. Genetyping HBV was analyzed by using Clustalxl. 81. msw. Resuits Totally 93 YMDD mutations and 1 patient( rtA181T)occurred in 109 patients experiencing virologic breakthrough. The 13 patients (8.6 % , 13/109)were not found YMDD mutation by sequencing but detected by RFLP. The substitutions at residues of LAM-r were rtM204V/I ( n = 93,85.3% ), rtL180M ( n = 51,46. 9% ) , rtV173L/M ( n = 7,6.4% ), rtV207M/L/l(n =4,3.7% ) ,rtAl81T(n =4,3.7% ) ,and rtM250L( n = 2,1.8% ). The major patterns of LAM-r HBV were identified, namely, rtM204V/I, rtA 181 T, rtM204V/I + rtL180M, rtM204V/I + rt L180M + rtV173 M and so on. Conclusion The major mutations with LAM-r are rtM204V/I and usually companied by rtL180M and rtVI73L/M mutations. A few LAM-r patients have adefovir and entecavir resistance before switihing to adefovir and entecavir.
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2008年第2期119-121,共3页 Chinese Journal of Practical Internal Medicine
基金 江苏省卫生厅科研项目(H200711) 上海市科委临床医学重点项目(054119529)
关键词 肝炎 乙型 慢性 肝炎病毒 变异 拉米夫定 耐药 hepatitis B, chronic hepatitis virus mutation lamivudine drug resistance
  • 相关文献

参考文献10

  • 1Hache C, Villeneuve JP. Lamivudine treatment in patients with chronic hepatitis B and cirrhosis[ J]. Expert Opin Pharmacother, 2006,7 ( 13 ) : 1835 - 1843. 被引量:1
  • 2Kazuaki C, Yoshiyuki S, Masahiro K, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamvudine therapy and re-takeover by wild type after cessation of therapy [ J ]. Hepatology, 1998,27 : 1711 - 1716. 被引量:1
  • 3陈立,张欣欣.核苷(酸)类似物耐药变异对乙型肝炎病毒生物学特性的影响[J].中国实用内科杂志,2007,27(15):1230-1232. 被引量:7
  • 4Zollner B, Sterneck M, Wursthom K, et al. Prevalence, incidence, and clinical relevance of the reverse transcriptase V207I mutation outside the YMDD motif of the hepatitis B virus polymerase during lamivudine therapy [ J ]. J Clin Microbiol, 2005,43 ( 5 ) : 2503 - 2505. 被引量:1
  • 5张继明.乙型肝炎病毒对拉米夫定的耐药性及防治[J].中国实用内科杂志,2007,27(11):894-897. 被引量:5
  • 6Daryl T, IJau Y, Everhart J, et al. Identification and characterization of mutations in HBV resistant to lamivudine [ J ]. Hepatology, 1998,27 : 1670 - 1677. 被引量:1
  • 7Yeh CT, Chien RN, Chu CM, et al. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy[ J ]. Hepatology,2000,31 (6) :1318 - 1326. 被引量:1
  • 8Hiromi Y, Chiemi N, Nobuhiko H, et al. Emergence of a novel Lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif [ J ]. Antimicrob Agents Chemother, 2006,50 ( 11 ) :3867 - 3874. 被引量:1
  • 9Tenney DJ, Rose RE, Baldick C J, et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present [ J ]. Antimicrob Agents Chemother, 2007,51(3) :902 -911. 被引量:1
  • 10Zhang JM, Yao X, Wang YX, et al. High replicative full-length lamivudine-resistant hepatitis B virus isolated during acute exacerbations [ J ]. J Med Virol, 2005,77 ( 2 ) : 203 - 208. 被引量:1

二级参考文献2

共引文献10

同被引文献115

引证文献13

二级引证文献69

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部